MedMira Inc
MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or who… Read more
MedMira Inc (MMIRF) - Net Assets
Latest net assets as of October 2025: $-23.37 Million USD
Based on the latest financial reports, MedMira Inc (MMIRF) has net assets worth $-23.37 Million USD as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.60 Million) and total liabilities ($26.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-23.37 Million |
| % of Total Assets | -650.1% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MedMira Inc - Net Assets Trend (2000–2025)
This chart illustrates how MedMira Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MedMira Inc (2000–2025)
The table below shows the annual net assets of MedMira Inc from 2000 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-07-31 | $-15.26 Million | +15.40% |
| 2024-07-31 | $-18.04 Million | -19.99% |
| 2023-07-31 | $-15.03 Million | -21.65% |
| 2022-07-31 | $-12.36 Million | +21.42% |
| 2021-07-31 | $-15.72 Million | -1.04% |
| 2020-07-31 | $-15.56 Million | -15.13% |
| 2019-07-31 | $-13.52 Million | -18.59% |
| 2018-07-31 | $-11.40 Million | -26.86% |
| 2017-07-31 | $-8.98 Million | -17.26% |
| 2016-07-31 | $-7.66 Million | +0.55% |
| 2015-07-31 | $-7.70 Million | -15.16% |
| 2014-07-31 | $-6.69 Million | +26.57% |
| 2013-07-31 | $-9.11 Million | -4.62% |
| 2012-07-31 | $-8.71 Million | +54.44% |
| 2011-07-31 | $-19.11 Million | -14.70% |
| 2010-07-31 | $-16.66 Million | -4.17% |
| 2009-07-31 | $-16.00 Million | -14.75% |
| 2008-07-31 | $-13.94 Million | -9.10% |
| 2007-07-31 | $-12.78 Million | -58.82% |
| 2006-07-31 | $-8.05 Million | +17.94% |
| 2005-07-31 | $-9.80 Million | -66.92% |
| 2004-07-31 | $-5.87 Million | -168.64% |
| 2003-07-31 | $-2.19 Million | +70.64% |
| 2002-07-31 | $-7.45 Million | -23.98% |
| 2001-07-31 | $-6.01 Million | -83.24% |
| 2000-07-31 | $-3.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MedMira Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10026146100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (July 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $68.67 Million | % |
| Other Comprehensive Income | $14.58 Million | % |
| Total Equity | $-22.56 Million | 100.00% |
MedMira Inc Competitors by Market Cap
The table below lists competitors of MedMira Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tractial S.A.
PA:ALTRA
|
$9.28 Million |
|
FiscalNote Holdings Inc.
NYSE:NOTE
|
$9.28 Million |
|
SWISS LIFE HLDG N
MU:SLW
|
$9.29 Million |
|
Kainantu Resources Ltd.
PINK:KRLCF
|
$9.29 Million |
|
Happy City Holdings Limited Class A Ordinary shares
NASDAQ:HCHL
|
$9.27 Million |
|
Codere Online Luxembourg S.A. Warrants
NASDAQ:CDROW
|
$9.27 Million |
|
Comfort Gloves Bhd
KLSE:2127
|
$9.27 Million |
|
Panora Gayrimenkul Yatirim Ortakligi AS
IS:PAGYO
|
$9.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MedMira Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -18,036,605 to -22,561,012, a change of -4,524,407.
- Net loss of 4,524,407 reduced equity.
- Other factors decreased equity by 0.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.52 Million | -20.05% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares MedMira Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-07-31 | $-0.16 | $0.07 | x |
| 2001-07-31 | $-0.29 | $0.07 | x |
| 2002-07-31 | $-0.36 | $0.07 | x |
| 2003-07-31 | $-0.09 | $0.07 | x |
| 2004-07-31 | $-0.14 | $0.07 | x |
| 2005-07-31 | $-0.22 | $0.07 | x |
| 2006-07-31 | $-0.17 | $0.07 | x |
| 2007-07-31 | $-0.21 | $0.07 | x |
| 2008-07-31 | $-0.17 | $0.07 | x |
| 2009-07-31 | $-0.14 | $0.07 | x |
| 2010-07-31 | $-0.09 | $0.07 | x |
| 2011-07-31 | $-0.09 | $0.07 | x |
| 2012-07-31 | $-0.02 | $0.07 | x |
| 2013-07-31 | $-0.02 | $0.07 | x |
| 2014-07-31 | $-0.01 | $0.07 | x |
| 2015-07-31 | $-0.01 | $0.07 | x |
| 2016-07-31 | $-0.01 | $0.07 | x |
| 2017-07-31 | $-0.01 | $0.07 | x |
| 2018-07-31 | $-0.02 | $0.07 | x |
| 2019-07-31 | $-0.02 | $0.07 | x |
| 2020-07-31 | $-0.02 | $0.07 | x |
| 2021-07-31 | $-0.02 | $0.07 | x |
| 2022-07-31 | $-0.02 | $0.07 | x |
| 2023-07-31 | $-0.02 | $0.07 | x |
| 2024-07-31 | $-0.03 | $0.07 | x |
| 2025-07-31 | $-0.03 | $0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MedMira Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1881.18%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 0.00% | -3694.04% | 0.02x | 0.00x | $-2.57 Million |
| 2001 | 0.00% | -1925.81% | 0.12x | 0.00x | $-6.60 Million |
| 2002 | 0.00% | -4935.31% | 0.03x | 0.00x | $-4.91 Million |
| 2003 | 0.00% | -392.35% | 0.50x | 0.00x | $-4.40 Million |
| 2004 | 0.00% | -163.71% | 1.44x | 0.00x | $-3.41 Million |
| 2005 | 0.00% | -229.51% | 1.86x | 0.00x | $-5.13 Million |
| 2006 | 0.00% | -348.46% | 0.52x | 0.00x | $-6.48 Million |
| 2007 | 0.00% | -368.70% | 0.60x | 0.00x | $-5.01 Million |
| 2008 | 0.00% | -460.34% | 1.83x | 0.00x | $-5.62 Million |
| 2009 | 0.00% | -462.64% | 2.17x | 0.00x | $-3.66 Million |
| 2010 | 0.00% | -411.74% | 1.89x | 0.00x | $-2.75 Million |
| 2011 | 0.00% | -537.68% | 0.61x | 0.00x | $-2.98 Million |
| 2012 | 0.00% | 347.43% | 0.33x | 0.00x | $4.24 Million |
| 2013 | 0.00% | -20.10% | 1.72x | 0.00x | $508.76K |
| 2014 | 0.00% | -151.70% | 1.37x | 0.00x | $-3.17 Million |
| 2015 | 0.00% | -79.70% | 2.27x | 0.00x | $-2.46 Million |
| 2016 | 0.00% | -228.57% | 2.59x | 0.00x | $-4.39 Million |
| 2017 | 0.00% | -356.07% | 1.11x | 0.00x | $-1.76 Million |
| 2018 | 0.00% | -426.15% | 1.96x | 0.00x | $-1.37 Million |
| 2019 | 0.00% | -399.37% | 2.09x | 0.00x | $-754.75K |
| 2020 | 0.00% | -222.55% | 0.27x | 0.00x | $-489.15K |
| 2021 | 0.00% | -31.51% | 0.55x | 0.00x | $896.59K |
| 2022 | 0.00% | -192.37% | 0.25x | 0.00x | $-595.98K |
| 2023 | 0.00% | -618.61% | 0.12x | 0.00x | $-1.17 Million |
| 2024 | 0.00% | -806.25% | 0.07x | 0.00x | $-1.52 Million |
| 2025 | 0.00% | -1881.18% | 0.07x | 0.00x | $-2.27 Million |
Industry Comparison
This section compares MedMira Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MedMira Inc (MMIRF) | $-23.37 Million | 0.00% | N/A | $9.28 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |